好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Multi-Site Validation of Human A?42 and Human Total Tau Assays for Use in Human CSF
Aging and Dementia
P03 - (-)
078
BACKGROUND: The MSD Human A?42 and Human Total Tau Kits have been validated internally for the detection of their respective analytes in human cerebrospinal fluid (CSF) using the "Fit for Purpose" criteria. Here we extend the validation of these kits to nine independent testing sites to assess their functional performance and the intra- and inter-center variability for each kit.
DESIGN/METHODS: All testing sites were trained by an MSD field application scientist prior to conducting the validation experiments. Each site tested standard curves, quality controls, and 12 blinded CSF sample pools in four discrete runs per assay over two days. Matrix tolerance was evaluated by dilution linearity using 10 CSF sample pools diluted 2- to 32-fold in two discrete runs per assay over two days. All samples were evaluated against pre-defined acceptance criteria.
RESULTS: The Human A?42 and Human Total Tau Kits produced similar standard curves and analyte measurements for both concentration and signal across all testing sites. A?42 levels in diluent-based QC samples and CSF sample pools were more variable than total tau levels. Trends observed for the QC samples and CSF sample pools were consistent across sample IDs for a given site and analyte.
CONCLUSIONS: A?42 and total tau levels measured in CSF sample pools correlate across all testing sites with coefficients of variation below 35 and 20 percent, respectively. We report that certain CSF sample pools exhibit large inter-center variability; ongoing studies are underway to determine the cause of sample-specific variability.
Authors/Disclosures
Pankaj Oberoi
PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
David A. Stamler, MD (Alterity Therapeutics) Dr. Stamler has received personal compensation for serving as an employee of Alterity Therapeutics. Dr. Stamler has stock in Alterity Therapeutics.
No disclosure on file
No disclosure on file